Every breath counts - because the right diagnosis at the right time is the gateway to care. At #WHA79 in Geneva, our Country Manager Germany Médard Schoenmaeckers joined discussions on how we turn global commitments into real-world delivery - including the 2025 WHO Lung Health Resolution and the wider NCD agenda. The Resolution is a landmark step - and the first time pulmonary fibrosis has been explicitly acknowledged in global health policy. But the real test is implementation: improving awareness, strengthening pathways to timely and accurate diagnosis, and ensuring high-quality care. Progress depends on effective collaboration between governments, civil society, multilateral organizations and industry. Here are a few key takeaways from the session - and what needs to happen next. #LungHealth #PulmonaryFibrosis #ChronicRespiratoryDiseases #HealthPolicy #NCDs
Boehringer Ingelheim
Fabricación de productos farmacéuticos
Ingelheim am Rhein, Rhineland-Palatinate 2.261.012 seguidores
Sobre nosotros
Boehringer Ingelheim figura entre las 20 compañías farmacéuticas líderes del mundo. Sus principales actividades son la investigación, el desarrollo, la producción y la comercialización de nuevos productos de alto valor terapéutico para la medicina humana y animal. Nuestra visión "Aportar valor a través de la innovación" ha caracterizado nuestro trabajo desde su fundación y es el motor y la base de nuestros principios corporativos. Alentamos a nuestros colaboradores y colaboradoras a optimizar los procesos ya existentes emprendiendo nuevos caminos y afrontando nuevos retos. En Boehringer Ingelheim, el trabajo en equipo y el intercambio de conocimientos son tan importantes como tener una actitud abierta y trato respetuoso con los demás. En Boehringer Ingelheim fomentamos el desarrollo personal y profesional de nuestros colaboradores y colaboradoras. Esto es así porque la compañía de propiedad familiar únicamente puede continuar teniendo éxito a largo plazo si garantiza la capacitación y motivación de sus trabajadores. Por ello, la compañía invierte en los conocimientos y en el saber hacer de sus equipos. Un buen ejemplo de ello es el trabajo basado en principios de liderazgo, pero también los programas específicos de desarrollo integrados en la BI-Academy, con una amplia oferta de cursos de formación e iniciativas sobre diversos temas. También la conciliación de la vida laboral y familiar es para nosotros un aspecto clave en el éxito de la empresa y la satisfacción en el puesto de trabajo. Además, Boehringer Ingelheim aporta numerosos beneficios sociales en el ámbito profesional y familiar, así como en el la jornada laboral y en el cuidado de la salud. Más información sobre el desarrollo de carrera: http://careers.boehringer-ingelheim.com
- Sitio web
-
http://www.boehringer-ingelheim.com
Enlace externo para Boehringer Ingelheim
- Sector
- Fabricación de productos farmacéuticos
- Tamaño de la empresa
- Más de 10.001 empleados
- Sede
- Ingelheim am Rhein, Rhineland-Palatinate
- Tipo
- De financiación privada
- Especialidades
- Pharmaceuticals, Animal Health, Innovation, Research, Health Care, Improve Health, Biopharmaceuticals y Contract Manufacturing
Ubicaciones
Empleados en Boehringer Ingelheim
Actualizaciones
-
A routine dog check-up involves hundreds of small decisions. Veterinarians observe small changes in behavior from the second an animal enters the clinic. They combine experience and years of training to assess each dog individually - adapting care in subtle ways that can go unnoticed if you’re not a vet yourself. Yet that’s how routine visits become personalized care. If you own a dog, don't be afraid to ask questions during appointments and make sure you get as much expert advice as possible. Bringing a list can help to cover everything that matters for your dog's health. 📋Download our guide for pet owners and be prepared for the next check-up: https://lnkd.in/dQViECWY
-
At #ATS2026, it’s been inspiring to hear directly from experts about new opportunities in #PulmonaryFibrosis care. With the unmet need in the field still high, it’s meaningful to see innovation opening new opportunities for patients and prescribers. #LifeForward
-
Spoiler alert. You don’t need a lab coat to make an impact here. Despite being a research-based pharmaceutical company, not all of us have a background in natural science. From pharmaceutical sciences and data, to IT and marketing, it's this blend of talent that drives our groundbreaking work. Apply now on our careers page: https://lnkd.in/guZFjt7u #LifeForward
-
-
#NEWS: Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved our treatment for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). Both conditions lead to an accelerated decline in lung function, massively impacting quality of life and claim many lives within only a few years of diagnosis. Learn more: https://lnkd.in/daYkKZBP #LifeForward #PulmonaryFibrosis
-
Living with idiopathic pulmonary fibrosis can feel isolating for both people living with the condition and those who care for them. In this video, Ron and his wife Maxine share how connecting with a support group helped them feel understood, supported, and less alone while navigating life with #IPF. Learn more about their story and the role support groups can play for people living with IPF and their carers: https://lnkd.in/dy_56urD #LifeForward #PulmonaryFibrosis
-
Through our collaboration with Mary Tyler Moore Vision Initiative, we’re working alongside universities, foundations, and pharmaceutical and biotech companies to better detect, prevent, and treat vision loss from diabetes. Learn why preserving real-world vision must remain at the center of innovation 👇 #EyeHealth
Looking back, #ARVO2026 was full of exciting insights, fruitful conversations and great achievements. We engaged in more than four Think Tank meetings, held 16 collaboration discussions, and conducted 57 advisor consultations. We also supported two educational forums and hosted three on-booth events and two 4SIGHT NETWORK meetings. A key achievement was reinforcing the importance of the patient voice in drug development at #ARVO2026. My colleague Olivia Meyerhoffer met with Dr. Robert Levine to discuss some of the takeaways from the first Patient-Focused Drug Development meeting on diabetic retinal disease, organized by Mary Tyler Moore Vision Initiative. The meeting focused on the lived experiences of patients and caregivers to help shape what the future of care and treatment looks like. Their conversation highlighted a point we feel strongly about: preserving real-world vision (not just acuity) must remain at the center of innovation. People living with diabetic retinal disease experience meaningful changes in how they see and navigate their daily lives long before traditional clinical measures catch up. Reading, preparing a meal, driving a car. These are the moments where vision loss becomes real, and where our science must meet patients. That’s why advancing more meaningful functional endpoints matters so much. We need to measure what patients actually experience, not just what instruments can detect. Thank you to Olivia, Robert, and everyone involved in this effort for bringing the patient perspective to the forefront so powerfully ! #EyeHealth #DiabeticRetinopathy
-
A routine cat check-up involves hundreds of small decisions. Veterinarians observe small changes in behavior from the second an animal enters the clinic. They combine experience and years of training to assess each cat individually - adapting care in subtle ways that can go unnoticed if you’re not a vet yourself. Yet that’s how routine visits become personalized care. If you own a cat, don't be afraid to ask questions during appointments and make sure you get as much expert advice as possible. Bringing a list can help to cover everything that matters for your cat's health. 📋Download a guide for pet owners and be prepared for the next check-up: https://lnkd.in/dQViECWY
-
Today, we announced a new global licensing agreement with Immunitas Therapeutics to advance a preclinical antibody program for inflammatory and autoimmune diseases. This first-in-class program selectively targets pathogenic immune cells at inflammation sites. With this approach, there’s a potential to deliver more durable, long-lasting disease control across a range of chronic conditions. Learn more about what this could mean for patients: https://lnkd.in/dd27jndu #Biopharma #Immunology #AutoimuneDiseases
-
-
“When patients speak, decision-makers listen,” says Christine Cockburn, CEO of Rare Cancers Australia. This belief is at the heart of why we're empowering patient organizations to advocate for systemic change and equitable access to care. As part of this effort, we co-created the white paper: "Real Voices, Better Choices", with Christine and a wider editorial board of patient advocates. It's a practical resource for policymakers and advocates to formalize patient participation and drive better health outcomes for everyone. Learn more about the context of the white paper here: https://lnkd.in/d_JQk-GA, and take a moment to think about how you can help drive #PatientPoweredProgress.
-